Based on the encouraging anti-tumor activity of BRD4 inhibition in hematological malignancies and solid tumors such as prostate cancer [17], glioblastoma [18], neuroblastoma [19], and lung cancer [20], a number of BRD4 inhibitors have entered clinical trials for cancer treatment [21]. This evidence concerns the gene BRD4 and cancer.